INT150422

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2006
Last Reported 2011
Negated 1
Speculated 1
Reported most in Body
Documents 24
Total Number 25
Disease Relevance 15.63
Pain Relevance 8.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Aes (Rattus norvegicus)
Pain Link Frequency Relevance Heat
withdrawal 24 99.48 Very High Very High Very High
Opioid 198 99.28 Very High Very High Very High
Oxycodone 357 98.36 Very High Very High Very High
narcan 286 97.84 Very High Very High Very High
abatacept 285 97.84 Very High Very High Very High
Ziconotide 480 97.52 Very High Very High Very High
Infliximab 279 97.04 Very High Very High Very High
Pain 283 94.12 High High
Analgesic 152 89.28 High High
Duloxetine 46 88.20 High High
Disease Link Frequency Relevance Heat
Akathisia 4 100.00 Very High Very High Very High
Vomiting 58 99.92 Very High Very High Very High
Opiate Addiction 12 99.66 Very High Very High Very High
Phobia 1 99.58 Very High Very High Very High
Death 56 99.36 Very High Very High Very High
Volume Depletion And Dehydration 6 98.92 Very High Very High Very High
Disease 222 98.84 Very High Very High Very High
Weight Gain 6 98.56 Very High Very High Very High
Psychosis 100 98.30 Very High Very High Very High
Cardiovascular Disease 10 98.16 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These prior studies differed from ours in several important ways: they evaluated patients not representative of adults in North American ICUs; they used different methodologies to capture information on complications; and, they did not perform survival analyses, which accounted for the time dependant nature of AEs.
Spec (analyses) Positive_regulation (accounted) of AEs
1) Confidence 0.43 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0 Pain Relevance 0
Patients were evaluated for AEs during therapy and until 28 days after the last study drug dose.


Positive_regulation (evaluated) of AEs
2) Confidence 0.23 Published 2010 Journal Br J Cancer Section Body Doc Link PMC2883700 Disease Relevance 0.98 Pain Relevance 0
One patient (patient 1) reported AEs (nausea and vomiting with dehydration) during treatment with ziconotide, but the AEs were considered unrelated to ziconotide therapy.49
Positive_regulation (reported) of AEs associated with ziconotide, volume depletion and dehydration and vomiting
3) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.80 Pain Relevance 1.75
However, compared with the two previous studies14,38 the current study had a higher incidence of AEs related to higher cortical functions, such as confusion and memory impairment.
Positive_regulation (incidence) of AEs associated with cognitive disorder and confusion
4) Confidence 0.22 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.80 Pain Relevance 0.79
Nine patients were withdrawn due to AEs and were not included in the efficacy analysis, but were included in the assessment of AEs.
Positive_regulation (assessment) of AEs
5) Confidence 0.22 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.90 Pain Relevance 0
No serious AEs or discontinuations as a result of AEs were reported during the study.
Positive_regulation (result) of AEs
6) Confidence 0.18 Published 2009 Journal Drugs Aging Section Body Doc Link 19220066 Disease Relevance 0 Pain Relevance 0
Treatment-emergent hepatobiliary adverse events (AEs) were compared for celecoxib <200 mg/day (943 patients), 200 mg/day (12 008 patients), 400 mg/day (7380 patients), and 800 mg/day (4602 patients); placebo (4057 patients); diclofenac 100-150 mg/day (7639 patients); naproxen 1000 mg/day (2953 patients); and ibuprofen 2400 mg/day (2484 patients).
Positive_regulation (ibuprofen) of AEs
7) Confidence 0.14 Published 2009 Journal Curr Med Res Opin Section Body Doc Link 19530981 Disease Relevance 0.07 Pain Relevance 0
All patients who received at least one dose of study drug were evaluated for safety, including all reported AEs, serious AEs (SAEs), and clinically significant changes in vital signs, physical exams, and clinical laboratory test abnormalities.
Positive_regulation (reported) of AEs associated with congenital anomalies
8) Confidence 0.08 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.38 Pain Relevance 0.35
All patients who received at least one dose of study drug were evaluated for safety, including all reported AEs, serious AEs (SAEs), and clinically significant changes in vital signs, physical exams, and clinical laboratory test abnormalities.
Positive_regulation (reported) of AEs associated with congenital anomalies
9) Confidence 0.08 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 0.38 Pain Relevance 0.35
Overall, AEs, related AEs and discontinuations due to AEs were also lower with abatacept than with infliximab (AEs: 89.1 vs 93.3%; related AEs: 46.2 vs 58.2%: and discontinuations due to AEs: 3.2 vs 7.3%, respectively).
Positive_regulation (related) of AEs associated with infliximab and abatacept
10) Confidence 0.08 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564802 Disease Relevance 1.01 Pain Relevance 1.07
These short-term trials suggest that iloperidone has a reassuring safety profile in many of the areas that are of potential concern, including relatively low dropout rates because of AEs, low extrapyramidal symptoms, akathisia, and prolactin elevation, and a modest short-term effect on weight gain.
Positive_regulation (elevation) of AEs associated with akathisia and weight gain
11) Confidence 0.06 Published 2008 Journal J Clin Psychopharmacol Section Abstract Doc Link 18334908 Disease Relevance 0.67 Pain Relevance 0.05
A total of 21 patients (5.2%) reported severe or life-threatening AEs: MF/F 200/10 ?
Positive_regulation (threatening) of AEs
12) Confidence 0.06 Published 2010 Journal The Journal of Asthma Section Body Doc Link PMC2993043 Disease Relevance 1.11 Pain Relevance 0.08
Overall, 153 patients (63.5%) reported TEAEs and two patients (both non-responders) experienced serious AEs during the study.
Positive_regulation (experienced) of AEs
13) Confidence 0.06 Published 2011 Journal International Journal of Clinical Practice Section Body Doc Link PMC3017744 Disease Relevance 0.70 Pain Relevance 0.11
Barriers to adherence thus include needle phobia and coping with the aforementioned AEs as well as others, but also include additional issues, such as not taking medication because of forgetfulness, complacency, treatment fatigue, changes in socioeconomic circumstances, and perceived lack of efficacy.24 Specifically related to GA, a study by Haas and Firzlaff of 308 patients with RRMS conducted over 24 months indicated a significantly (P < 0.001) lower discontinuation rate for GA compared with the 3 IFN-based therapies.25 However, regardless of whether patients are treated with IFN?
Positive_regulation (aforementioned) of AEs associated with phobia, multiple sclerosis and fatigue
14) Confidence 0.04 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857614 Disease Relevance 0.49 Pain Relevance 0.10
In an analysis (pers comm Jan 8 2008, Bristol-Myers Squibb and Otsuka Pharmaceutical Co, Ltd, Data on file) of the three 10-week, placebo-controlled studies of aripiprazole in elderly patients with psychosis associated with AD (n = 938, mean age 82.4 years, range 56–99 years), the treatment-emergent AEs that were reported at an incidence of ?
Positive_regulation (emergent) of AEs associated with psychosis and disease
15) Confidence 0.04 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682381 Disease Relevance 0.68 Pain Relevance 0
Safety and tolerability of a medication is of great concern while treating the elderly due to their increased sensitivity to adverse events (AEs), the increased likelihood of co-morbid health problems (eg, cardiovascular disease), and the potential for some side effects to worsen the progression of dementia (Kindermann et al 2002).
Positive_regulation (increased) of AEs associated with dementia and cardiovascular disease
16) Confidence 0.04 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682381 Disease Relevance 0.97 Pain Relevance 0
Two patients reported an AE related to opioid withdrawal (drug withdrawal syndrome); however, both AEs started after the end of study medication intake and were, therefore, probably related to the change of opioid treatment.
Positive_regulation (related) of AEs associated with withdrawal and opioid
17) Confidence 0.04 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 1.33 Pain Relevance 0.59
Two patients reported an AE related to opioid withdrawal (drug withdrawal syndrome); however, both AEs started after the end of study medication intake and were, therefore, probably related to the change of opioid treatment.
Positive_regulation (started) of AEs associated with withdrawal and opioid
18) Confidence 0.04 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 1.29 Pain Relevance 0.58
Fewer than half of the patients (125; 48.4%) experienced AEs considered as having a causal relationship to study medication, which were classified as serious for only eight patients (3.1%).
Positive_regulation (experienced) of AEs
19) Confidence 0.04 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 0.69 Pain Relevance 0.77
Furthermore, there was no indication of an increased risk of AEs in patients taking doses > 40/20 mg/day oxycodone PR/naloxone PR for > 7 days consecutively, compared with the total extension phase population.


Positive_regulation (increased) of AEs associated with oxycodone and narcan
20) Confidence 0.04 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2948431 Disease Relevance 0.58 Pain Relevance 0.91

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox